

References

1. Abbott R. Complications with selective posterior rhizotomy. *Pediatr Neurosurg* 1992; 18(1): 43-7.
2. ACOG Technical bulletin: Chronic pelvic pain, number 223 — May 1996 *Tnt. J; Gynecol & Obstet* 1996; 54: 59-68.
3. Ahmedzai S and Brooks D. Transdermal fentanyl versus sustained release oral morphine in cancer pain: Preference, efficacy, and quality of life-the TTS-Fentanyl Comparative Trial Group. *J Pain Symptom Manage* 1997; 13: 254-261.
4. Aner MM and Warfield CA. Neurolytic Blocks In : Principles & Practice of Pain Medicine. Warfield CA, and Bajwa ZH (Eds). McGraw-Hill, 2004.
5. Aparasu R, McCoy RA, Weher C, et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. *J Pain Sympt Manage* 1999; 18: 280-288.
6. Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. *J Clin Pharmacol* 1998; 38:74-81.
7. Bach FW [Beta]-endorphin in the brain. A role in nociception: The Acta Anaesthesiologica Foundation 1997; 41: 133-140.
8. Bassam D, Cephas GA, Ferguson KA, et al. A protocol for the initial management of unstable pelvic fractures. *Am Surg* 1998; 64: 862-867.
9. Becker N, Thomsen AB, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. *Pain* 1997; 73: 393-400.
10. Berkley KJ Female vulnerability to pain and the strength to deal with it. *Behav & Brain Sci* 1997b 20: 473-479.
11. Bernstein AK Philips HC, Linden W, et al. A physiological evaluation of female urethral syndrome: evidence for a muscular abnormality. *J Behav Med* 1992; 15: 299-312.
12. Berry MM, Standring SM, and Bannister LH. Nervous system, *Grays Anatomy*, 38th edition. Williams PL, Bannister LII, Berry MM, Collins P, Dyson M, Dussek JE, and Ferguson MWJ (Eds). New York, Churchill Livingstone 1995; pp: 901-1397.
13. Bjerklund and Weidner U-. Understanding chronic pelvic pain syndrome. *Curr Opin Urol* 2002; 12(1): 63-67.
14. Boas RA. Phantom anus pain syndrome. In: Bonica JJ, Lindlom U, Iggo A, eds. *Advances in pain research therapy*. New York: Raven, 1983; PP: 947-957.

15. Bornstein J, Zarfati D, Goldshmid N, et al. Vestibulodynia a subset of valvular vestibulitis or a novel syndrome? *Am J Obstet Gynecol* 1997; 177(6): 1439-43.
16. Brown DL and Rorie DL. Altered reactivity of isolated segmental lumbar arteries of dogs following exposure to ethanol and phenol. *Pain* 1994; 56: 139.
17. Bruera E and Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. *Pain* 1997; 69: 199—201.
18. Butter SH and Chart/on .JE. Neurolytic blockade and hypophysectomy. In: Bonica's management of pain. Loeser JD, Butler SH, Chapmon CR, and Turk DC (Eds): Lippincott Williams and Williams 2001.
19. Caraceni A and Portenoy RK. An international survey of cancer pain characteristics and syndromes. *Pain* 1999; 82: 263-274.
20. Cariati M, De Martini G, Pretolesi F, et al. CT-guided superior hypogastric plexus block. *3 Comput Assist Tomogr* 2002; 26(3): 428-3 1.
21. Cashnian JN. The mechanisms of action of NSAIDs in analgesia. *Drugs* 1996; 52(suppl 5): 13-23.
22. Cervero FandLandf. Visceral pain. *Lancet* 1999; 353: 2145-2148.
21. Cervero F. Sensory innervation of the viscera: peripheral basis of visceral pain. *Physiol Rev* 1994; 74: 95-13 8.
23. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. *J Clin Oncol* 2001; 19(9): 2542-54.
24. Cleel and CS, Gonin R, Harfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med* 1994; 330: 592—596.
25. Collins .JJ, Liii CE, and Berthand HR. Vagal afferents from the uterus and cervix provide divers connections to the brain stem. *Cell Tissue Res* 1999; 295: 43-54.
26. Cousins MI and Bridenbaugh P0. Neural Blockade. In: *Clinical Anesthesia and Management*, 3 ed. New York: Lippincott-Raven, 1998.
27. Cousins MI and Plummer JL. Spinal opioids in acute and chronic pain, in: *Advances in pain research mid therapy*, Max MB, Portenoy RK and Laska EM (Eds). New York: Raven Press, 1991; pp: 479.
28. Cox DL, Stez J, and Pajak TE. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *mt 3 Radiat Onco Biol Phys* 1995; 31(5): 1341-1346.
29. Cullinane CA, Chu DJZ, and Manielak AN. Current surgical options in the control of cancer pain. *Cancer Pract* 2002; 10 Suppl 1:S2 1-6.
30. Dangor 1', Ballard RC, and Miller SD. Treatment of chancroid. *Antimicrob Agents Chemoth* 1990; 34: 1308-1311.

31. De Conno F, Caraceni A, Martini C, et al Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. *Pain* 1991; 47: 337-339.
32. De Leon-Casasola OA. Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. *Cancer Control* 2000; 7(2): 142-148.
33. De Leon-Casasola OA and Ditonto E. Drugs commonly used for nerve blocking: Neurolytic Agents. In: *Practical Management of Pain*. 3 ed. Raj PP (Ed): St Louis, Mosby Year Book 2000; PP: 575-576.
34. De Oliveira R, dos Reis MP, and Prado WA. The effects of early and late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain. *Pain* 2004; 110: 400-408.
35. Deletis V, Vodusek DB, Abbott R, et al Intraoperative monitoring of the dorsal sacral roots: minimizing the risk of iatrogenic micturition disorders. *Neurosurgery* 1992; 30(1): 72-5.
36. Dewey WL. Structure-activity relationships. In: *Endorphins: Chemistry, physiology, pharmacology and clinical relevance*. Malick JB and Bell RM (Eds.) New York: Marcel Dekker 1982: 23-56.
37. Dwyer FL and O'Reilly U Recurrent urinary tract infection in the female. *Current Opinion in Obstetrics and Gynecology*; 2002; 14(5): 537-543.
38. Ellison NM. Opioid analgesics: Toxicities and their treatment. In: *Patt RB (Ed). Cancer Pain*, Philadelphia PA, Lippincott, 1993; P: 185.
39. Ferrante FM, Bedder M, Caplan RA, et al Practice guidelines for cancer pain management. *Anesthesiology* 1996; 84: 1243-1257.
40. Fink BR. Mechanism of hypo-osmotic conduction block. *Reg Anesth* 1980; 5: 7.
41. Fujita I'. CT-guided neurolytic splanchnic nerve block with alcohol. *Pain* 1993; 55: 363.
42. Genazzani AR, Nappi G, Fachinetti F, et al Progressive impairment of CSF beta-endorphin levels in migraine sufferers. *Pain* 1984: 1127-33.
43. Grossman SA, Sheidler VR, Swedeen K, et al Correlation of patient and caregiver ratings of cancer pain. *J Pain Symptom Management* 1991; 6: 53-57.
44. Güllner HG, Nicholson WE, Wilson MG, et al The response of plasma immunoreactive adrenocorticotropin, β -endorphin, β -lipotropin, γ -lipotropin and cortisol to experimentally induced pain in normal human subjects. *Clin Sci* 1982; 63: 397-400.
45. Gupthill WE and Carr DB. Cancer pain assessment and management: a survey. *Journal of Back and Musculoskeletal Rehabilitation* 1999; 12: 89-99.
46. Han KR, Jung JW, Seo MS, et al Effects of neurolysis of the ganglion impar on the hyperhidrosis in the buttock and perineum. *J Korean Pain Res Soc* 2001; 11: 114-8.

47. Hanks OW, De Conno F, Ripaniontt C, et al Morphine in cancer pain; modes of administration. *Br Med* 1996; 312: 823-826.
48. Harrison P. Update on pain management for advanced genitourinary cancer. *The Journal of Urology* 2001; 165(0): 1849-1858.
49. Hassenbusch Sf, Paice JA, Pat! RB, et al. Clinical realities and economic considerations: economics of intrathecal therapy. *J Pain Symptom Manage* 1997; 14: 536-548.
50. Hassenbusch SJ, Stanton-Hicks M, Covington EC, et al. Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. *J Pain Symptom Management* 1995; 10: 527-543.
51. Head H. On disturbances of sensation with special reference to the pain of visceral disease. *Brain* 1993; 16: 1-113.
52. Heavner JE, Racz GB. Gross and microscopic lesions produced by phenol neurolytic procedures. In: *Techniques of Neurolysis*. Racz GB (Ed): Kluwer Academic Publishers, Boston 1989; P: 27.
53. Heikal AMY, Abdel-Aziem MA, and Zohdy AA. Posterior sacral rhizotomy versus superior hypogastric plexus block in the control of urinary bladder cancer pain. *JESMP* 2001; 19(1): 1-14.
54. Herbs! AL. *Comprehensive Gynecology*, 3rd ed. St Louis, Mosby 1997; PP: 156-159.
55. Hiroshi I, Shigehito S, and Yoshito S. Saddle block using 10-20 % tetracaine for patients with perineal pain due to recurrent rectal cancer. *Anesthesiology* 2003; 98(3): 781-783.
56. Hocking G and Williams JAW. Intrathecal drug spread. *Br J Anaesth* 2004; 93(4): 568-78.
57. Howard FM. The role of laparoscopy in chronic pelvic pain: promise and pitfalls. *Obstet Gynecol Surv* 1993; 48: 357-387.
58. Huang JC, Deletis V, Vodusek DB, et al. Preservation of pudendal afferents in sacral rhizotomies. *Neurosurgery* 1997; 41(2): 411-5.
59. Huang JJ. Another modified approach to the ganglion of Walther block (ganglion impar). *J Chin Anesth* 2003; 15: 282-3.
60. Ischia S, Luuani A, Pacini L, et al. Lytic saddle block: Clinical comparison of the results, using phenol at 5, 10 and 15 percent. *Adv Pain Res Ther* 1984; 7: 339.
61. Jean- Jives M, Levon D, Gilles C. Causes and mechanisms of common coccydynia: Role of body mass index and coccygeal trauma. *Spine* 2000; 25(33): 3072-3079.
62. Jenkins CA, Bruera E. Non-steroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. *Palliat Med* 1999; 13: 183-196.
63. Jessop DS. Beta-endorphin in the immune system-mediator of pain and stress. *Lancet* 1998; 351: 1828-9.
64. Johnson JG. Gynecologic pain: Locating its source. *Pain Management* May/June 1990; PP: 143-152.

65. Kanner R. Diagnosis and management of neuropathic pain in patients with cancer. *Cancer Investigation* 2001; 19(3): 324-333.
66. Kapoor D, Ghoniem GM, and Davila W. Gynecologic pain, October 18, 2004; e-medicine.
67. Kapural L and Mekhail N. Radiofrequency ablation for chronic pain control. *Cuff Pain Headache Rep* 2001; 5(6): 5 17-525.
68. Kawamata M, Ishitani K, Ishikawa K, et al. Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. *Pain* 1996; 64: 597—602.
69. Keef FJ, Rumble ME, Scipio CD et al. Psychological aspects of persistent pain. *Current State of Science. The Journal of Pain* 2004; 5(4): 195-211.
70. Kermit E, Krantz MD, and Lit! D. Anatomy of the Female Reproductive System. In: *Current Obstetrics & Gynecologic Diagnosis & Treatment*. DeCherney, Alan H., Nathan, and Lauren (Eds). McGraw-Hill, 2003.
71. Korsten HHM, Hellebrekers U, Grouls RJE, et al. Long-lasting epidural sensory blockade by n-Butyl p-aminobenzoate in the dog: Neurotoxic or local anesthetic effect? *Anesthesiology* 1990; 73: 491.
72. Lee HK, Yang SK, Lee SY, et al. The effect of ganglion impar block for excessive perianal sweating. *J Korean Pain Soc* 1995; 8: 363-6.
73. Lepdri re T. Psychogenic pain. *Psychosomatic Symptoms* 1990; PP: 49-51.
74. Levine FJ, Saenz de Tejada I, Payton TR, et al. Recurrent prolonged erections and priapism as a sequela of priapism: pathophysiology and management. *J Urol* 1991; 145: 764.
75. Lipton S. Pain relief in active patients with cancer: the early use of nerve blocks improves the quality of life. *Brit Med J* 1989; 298: 37-38.
76. Loev M, Varkict VL, Wilsey BL, et al. Cryoablation: A novel approach to neurolysis of the ganglion impar. *Anesthesiology* 1998; 88: 1391-3.
77. Lyons PD and Blalock JE. Pro-opiomelanocortin gene expression and protein in rat mononuclear leucocytes. *J Neuroimmunol* 1997; 78: 47-58.
78. M. Kame4 R. Said: Synopsis of algology. *Diagnosis of cancer pain*, 1991; part III: 41-42.
79. Max MB, Donovan M, Portenoy RK, et al. American Pain Society quality assurance standards for relief of acute pain and cancer pain. In: *Proceedings of the sixth world congress on pain*. Bond MR, Charlton JR and Woolf CJ, (Eds). New York: Elsevier, 1991; PP: 185-189.
80. Mayo ME, Ross SO, and Krieger JN: Few patients with “chronic prostatitis” have significant bladder outlet obstruction. *Urology* 1998; 52: 417-421.

81. McAllister RK, Carpentier BW, Mailcuch G. Sacral post herpetic neuralgia and successful treatment using a paramedical approach to the ganglion impar. *Anesthesiology* 2004; 101:1472-1474.
82. McDonald and Alo' KM. Pelvic and perineal pain of urologic origin. In: Bonica's Management of pain. Loeser JD, Butler SH, Chapman CIRCUMFLEX and Turk DC (Eds): Lippincott Williams and Williams 2001.
83. McDonald JS and Loeser JD. Pelvic and perineal pain caused by other disorders. In: Bonica's Management of pain. Loeser JD, Butler SH, Chapman CR and Turk DC (Eds): Lippincott Williams and Williams 2001.
84. McDonald JS and Rapkin AJ. General Considerations. In: Bonica's Management of Pain. Loeser JD, Butler SH, Chapman CR and Turk DC (Eds): Lippincott Williams and Wilkins 2001.
85. McGrath P and McAlpine L. Psychologic perspectives on pediatric pain. *J Pediatrics* 1993; 122: 52-58.
86. McMahan SB, Dmitrieva N and Koltzenberg M. Visceral pain. *Br J Anesth* 1995; 75: 132-144.
87. Melzack P. Pain: past, present and future. *Can J Exp Psychol* 1993; 47: 615-629.
88. Mercadante S, Fulfarò F, and Casuccio A. Pain mechanisms involved and outcome in advanced cancer patients with possible indications for celiac plexus block and superior hypogastric plexus block. *Tumori* 2002; 88: 243-245.
89. Mercadante S, Salvaggio L, Dardanoni G, et al. Dextropropoxyphene versus morphine in opioid-naïve cancer patients with pain. *J Pain Symptom Manage* 1998; 15: 76-81.
90. Mercadante S. Celiac plexus block versus analgesic in pancreatic cancer pain. *Pain* 1993; 52: 87-92.
91. Mercadante S. Malignant bone pain: pathophysiology and treatment. *Pain* 1997; 69: 1.
92. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. *Cancer* 1999; 86: 1856-66.
93. Merskey H, Bogduk N Classification of chronic pain. Seattle: IASP Press, 1994.
94. Moldwin R and Sant GR. Interstitial cystitis: A pathophysiology and treatment update. *Clin Obstet Gynecol* 2002; 45(1): 259-272.
95. Moor J, Barlow D, Jewel D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual cycle? *Br J obstet Gynaecol* 1998; 105: 1322-1325.
96. Munir MA, Zhang J, and Ahmad M. A modified needle-inside-needle technique for the ganglion impar block. *Can J Anaesth* 2004 ; 5(9):9 15-7.

97. Myers RR, James HE and Powell HC. Laser injury of peripheral nerve: A model for focal endoneurial damage. *J Neurol Neurosurg Psychiatry* 1985; 48: 1265.
98. Myers RR, Yamamoto T, Yaksh TL and Powell HC. The role of focal nerve ischemia and Wallerian degeneration in peripheral nerve injury producing hyperesthesia. *Anesthesiology* 1993; 78: 308.
99. Myers RR. Neuropathology of neurolytic agents. In: *Neural Blockade in Clinical Anesthesia and Management of Pain*, 3rd ed. Cousins MJ and Bridenbaugh PO (Eds): Lippincott-Raven, Philadelphia, New York, 1998.
100. Nasr F, Nayel H, and Abdel Ghaffar S. Subarachnoid opiate versus neurolytics in management of advanced pelvic cancer pain. *JESMP* 1989; 7(2): 235-244.
101. Nebab EG and Florence IM. An alternative needle geometry for interruption of the ganglion impar. *Anesthesiology* 1997; 86(5): 1213-4.
102. Nelson KA, Glare PA, Walsh D, et al. A prospective within-patient, crossover study of continuous intra-venous and subcutaneous morphine for chronic cancer pain. *J Pain Symptom Manage* 1997; 13: 262-267.
103. Niv D and Kreitzer S. Pain and quality of life. *Pain Practice* 2001; 1 (2): 150-161.
104. North RB. Spinal cord stimulation for chronic intractable pain. In: *Electrical and magnetic stimulation of the brain and spinal cord*. Devinsky O, Beric A, and Dogali M (Eds): New York, Raven Press, 1993.
105. Novicki DE, Larson TR, and Swason SK. Interstitial cystitis in men. *Urology* 1998; 52: 621-624.
106. Oh CS, Chung IH, Ji HJ, et al. Clinical implications of topographic anatomy on the ganglion impar. *Anesthesiology* 2004; 101(10): 249-50.
107. Osmon KB and Pienta KJ. Pain management in patients with advanced prostate cancer. *Oncology* 1999; 13: 1537.
108. Ovesen P, Kroner K, Orskov J, et al. Phantom-related phenomena after rectal amputation: prevalence and clinical characteristics. *Pain* 1991; 44: 289-91.
109. Paice JA, Penn RD and Shaft S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. *J Pain Symptom Management* 1996; 11:71-80.
110. Panerai AE, Martini A, Abbate D, et al. Beta-endorphin, met-enkephalin and beta-lipotropin in chronic pain and electroacupuncture. In: *Advances in Pain Research and Therapy*. Bonica JJ et al. (Eds.). Raven Press, N.Y 1983; 5: 1543-47.
111. Papapoulos SE. Paget's disease of bone: clinical, pathogenetic and therapeutic aspects. *Baillieres Clin Endocrinol Metab* 1997; 11: 117-143.
112. Pasternak GW. The pharmacology of mu analgesics: from patients to genes. *Neuroscientist* 2001; 7: 220-231.

113. Patt RB and Cousins MJ. Techniques for neurolytic neural blockade. In: Neural blockade in clinical anesthesia and management of pain, 3 ed. Cousins MJ and Bridenbaugh PO (Eds): Lippincott-Raven, Philadelphia 1998; PP: 1007-1061.
114. Patt RB. Cancer Pain. In: Surgical Management of pain. Burchiel K (Ed): Thieme, New York, Stuttgart, 2002; PP: 469-484.
115. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* 1998; 16:1588-1593.
116. Pereira J, Laower P, Vigano A, et al. Equianalgesic dose ratios for opioids: a critical review proposals for long-term dosing. *Pain Symptom Manage* 2001; 22: 672-86.
117. Petronis JD, Regan F, Lii K. Indium-111 capromab pendetide (Prosta-Scint) imaging to detect recurrent and metastatic prostate cancer. *Clin Nucl Med* 1998; 23: 672-677.
118. Plancarte R and Valazquez P. Neurolytic blocks of the sympathetic axis, In: Cancer Pain. Patt R (Ed). Philadelphia, Lippincott Williams & Wilkins 1993; pp: 4 17-20.
119. Plancarte R, Amescua C, and Pall RB. Presacral blockade of ganglion impar (ganglion of Walther). *Anesthesiology* 1990; 73: A751.
120. Polati E, Funco G, Gottin L, et al. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. *British Journal of Surgery* 1998; 85(2):199-201.
121. Portenoy RK, Payne D, and Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. *Pain* 1999; 81: 129- 134.
122. Potter JM, Reid DB, Shaw RJ, et al. Myoclonus associated with treatment with high doses of morphine: The role of supplemental drugs. *BMJ* 1989; 299: 150-153.
123. Raj PP, Lou L, Erdine S, et al. Ganglion impar block. In: Radiographic Imaging for Regional Anesthesia and Pain Management. New York, Churchill Livingstone, 2003; pp: 238-41.
124. Redd WH. Behavioral intervention for cancer treatment side effects. *Acta Oncologica* 1994; 33: 113-117.
125. Reig E, Abejon D, del Poz C, et al. Thermocoagulation of the Ganglion Impar or Ganglion of Walther: Description of a Modified Approach. Preliminary Results in Chronic, Nononcological Pain. *Pain Practice* 2005; 5(2): 103-110.
126. Reiter R C. A profile of women with chronic pelvic pain. *Clin Obstet Gynecol* 1990; 33: 130-136.
127. Reiter RC Occult somatic pathology in women with chronic pelvic pain. *Clinical Obstetrics and Gynecology* 1998; 41(3): 154-160.
128. Rigor BM. Pelvic cancer pain. *J Surg Oncol* 2000; 75(4):280-300.

129. Ripamonti C and Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. *Drugs* 2001; 61: 955-977.
130. Ro C and Cramer G. The sacrum, sacroiliac joint and coccyx, In: *Basic and Clinical Anatomy of the Spine, Spinal Cord, and ANS*. Cramer G, Darby S (Eds). St.Louis: Mosby-Year Book; 1995: 24 1-2.
131. Rogers RM Basic Neuroanatomy for understanding pelvic pain. *3 Am Assoc Gynecol Laparosc* 1999; 6: 15.
132. Rosse C and Gaddum-Rosse F. Hollinsheads Textbook of Anatomy, 5th edition. Philadelphia, Lippincott-Raven 1997; pp: 652-3.
133. Rowe DS. Neurolytic techniques for pain management. *Jacksonville Medicine*, 1998.
134. Rummans TA, FrostM, Suman V. etal. Quality of life and pain in patients with recurrent breast and gynecologic cancer. *Psychosomatics*. 1998 ;39 :43 7-445.
135. Rykowski .1.1 and Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer. *Anesthesiology* 2000; 92: 347-54.
136. Saberski L and Ligham D. Neuroablative techniques for cancer pain management. In: *Techniques in Regional Anesthesia and Pain Management*. Urme y W, (Ed). Philadelphia, Pa: WB Saunders; 1997; Vol 1, No 1.
137. Samuelson H and Hedner T. Pain characterization in cancer patients and the analgesic response to epidural morphine. *Pain* 1991; 46: 3-8.
138. Schaeffer AJ. Prostatitis: US prespective. *mt j Antimicrob Agents* 1998; 10: 153-159.
139. Schlumb JC Chronic somatic, yofascial, and neurogenic pelvic pain. *Clin Obst Gynecol* 1990; 33(1): 145-53.
140. Segrenti EM, Kavanagh BD, Wheelock J. Palliative care of the patient with advanced Gynecologic Cancer e-medicine 2004.
141. Sehaeffer AJ. Infection and inflammation of the genitourinary tract. *Journal of Urology* 2003; 169(1): 414-420.
142. Sharfman WH and Walash TD. Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain? *Pain* 1990; 41:267-71.
143. Simons DG, Travel! JG, and Simons LS. Myofascial pain and dysfunction. In: *The Trigger Point Manual*, 2' ed. Baltimore (Ed), Williams & Wilkins, 1999.
144. Sins ES. Paget's disease of bone. *J Bone Miner Res* 1998; 13: 1061-1065.
145. Sommer C, La!onde A, Heckman HM, Rodriguez M and Myers RR. Quantitative neuropathology of a focal nerve injury causing hyperalgesia. *J Neuropath Exp Neurol* 1995; 54: 635.

146. Stein C. The control of pain in peripheral tissues by opioids. *N Engl J Med* 1995; 332: 1685-1690.
147. Stjernsward J, Cotteau SM, and Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, Present, and Future. *J Pain Symptom Manage* 1996; 12: 65-72.
148. Sunderland S. The anatomical basis of nerve repair. In: Nerve repair and regeneration. Jewett DL, and McCarroll Jr HR (Eds): CV Mosby, St Louis, 1980; P: 14.
149. Sweetman and Sean C Phenol and Glycerol Injection. In: The Complete Drug Reference. Martindale (Ed). Pharmaceutical Press (Publications division of the Royal Pharmaceutical Society of Great Britain), 2004.
150. Syrjala KL, Cummings C and Donaldson GW Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment. A Controlled clinical trial. *Pain* 1992; 48: 137-146.
151. Takano M, Juromizu J, and Tsuji V. Pathogenesis of proctalgia fugax is clarified. *Dis Colon Rectum* 1996; 39: A28.
152. Thomas PK and Holdroff B. Neuropathy due to physical agents. In: Peripheral Neuropathy. Dyck PJ and Thomas PK (Eds):. WB Saunders, Philadelphia, 1993; P: 990.
153. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects. A survey in cancer patients. *Pain* 1995; 61: 47-54.
154. Trapezinkova MF, Bazev VJ4 Urenkov SB. Transurethral resection in patients with benign prostatic hyperplasia complicated by chronic calculous prostatitis. *Urol Nefrol (Mosk)* 1997; 1: 28-31.
155. Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. *Bone* 1991; 12(suppl): 59.
156. Ummenhofer WC, Arends RH, Shen DD, et al. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil. *Anesthesiology* 2000; 92(3): 739-753.
157. Van Zundert J, Raj PP, Erdine S, et al. Application of radiofrequency treatment in practical pain management: state of the art. *Pain Pract* 2002; 2:269-278.
158. Vanegas G, Ripamonti C, Sbanotti A, et al. Side effects of morphine administration in cancer patients. *Cancer Nurs* 1998; 2 1(4): 289-97.
159. Ventafridda V and Stjernsward J. Pain control and the World Health Organization Analgesic Ladder. *JAMA* 1996; 275: 835-36.
160. Ventafridda V. Caraceni AT, Sbanatto Aj11 et al. Pain treatment in cancer of the pancreas. *Eur J Surg Oncol* 1990; 16: 1-6.
161. Ventafridda V. Oliveri E, Caraceni A, et al. A retrospective study on the use of oral morphine in cancer pain. *J Pain Symptom Manage* 1987; 2: 77- 81.

162. Vodusec DR. Neurogenic bladder dysfunction. *European Journal of Neurology* 2003; 7.
163. Von Knorring L, Johansson F, and Alamy BC The importance of the endorphin systems in chronic pain patients. In: *Endorphins and opiate antagonists in psychiatric research: Clinical implication*. Shah NS and Donald AG (Eds). New York: Plenum 1982: 407-26.
164. Von Roenn JH, Cleeland Cs, Gonin R, et al Physician's attitudes and practice in cancer pain management: A survey from the Eastern Cooperative Oncology Group. *Ann Intern Med* 1993; 119: 121-126.
165. Vranken JH, Zuurmond WWA, and De Lange .1.1. Increasing the efficacy of a celiac plexus block in patients with severe pancreatic cancer pain. *J Pain Symptom Manage* 2001; 22: 966-77.
166. Wemm K J and Saberski L. Modified approach to block the ganglion impar (ganglion of Walther). *Reg Anesth* 1995; 20: 544-5.
167. Wesselmann U. Pain of pelvic origin. (Urological and Gynecological; In: Mitchell Max (ed.). *An updated Review refresher course*. I.A. S .P. Scientific Program Committee. 1999; pp. 47-58.
168. Winkelmuller M and Winkemuller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain a! nonmalignant etiology. *3 Neurosurg* 1996; 85: 458-467.
169. Xue B, Lema MJ and de Leon-Cassasola. Ganglion impar block. In: *Essentials of pain Medicine and Regional Anesthesia*. Benzon HT, Raja SN, Borssok D, Molloy RE and Strichartz G (Eds). Churchill Livingstone 1999: 329-33 1.
170. Yco SN and Chong JL. A case report on the treatment of intractable pain from metastatic carcinoma of the cervix. *Ann Acad Med Singapore* 2001; 30: 632-5.
171. Zech DF, Grond 5, Lynch J, et al Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. *Pain* 1995; 63(1): 65-76.